From Globe Newswire: 2024-06-08 16:30:00

4D Molecular Therapeutics presented supplemental analysis showing injection-free results of its Phase 2 PRISM trial for wet age-related macular degeneration (AMD). A single intravitreal dose of 4D-150 demonstrated stable visual acuity and reduced central subfield thickness compared to aflibercept through 24 weeks. The study showed promising results for improving retinal anatomy and vision in severe wet AMD patients without additional treatment. Additional data from the Population Extension cohort will be presented at the ASRS Annual Scientific Meeting in July 2024, with Phase 3 trial design updates expected later in the year. Wet AMD affects millions worldwide and can lead to blindness without treatment.



Read more at Globe Newswire: 4DMT Presents Injection-Free Subgroup Analyses from 4D-150